DAWN Q4 2022 Earnings — Day One Biopharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena

DAWNDay One Biopharmaceuticals, Inc.

$2B

Q4 2022 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$0

Gross Profit

-$180,000

Operating Income

-$43M

Net Income

-$40M

EPS (Diluted)

$-0.47

QoQ Revenue Growth

NaN%

Cash Flow

Operating Cash Flow

-$35M

Free Cash Flow

-$35M

Stock-Based Comp.

$7M

Balance Sheet

Total Assets

$349M

Total Liabilities

$17M

Stockholders' Equity

$332M

Cash & Equivalents

$85M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$0	$0	—
Gross Profit	-$180,000	-$51,000	-252.9%
Operating Income	-$43M	-$22M	-94.5%
Net Income	-$40M	-$22M	-82.8%